United Therapeutics (UTHR) Stock Forecast & Price Target

United Therapeutics is viewed favorably because the '327 settlement sharply reduces legal uncertainty around Yutrepia, brings $330.4M in damages plus about $50.3M in net antitrust benefit, and creates a clearer path for Tyvaso to recapture PH-ILD patients. The settlement’s restrictions on off-label use, payer denials, and mandatory PAH certification should limit competitive erosion, supporting the Tyvaso franchise, which is still the company’s maximum-revenue product and is expected to retain a 67% market share after a 6% decline versus 2Q26. Beyond the near term, the company has multiple growth drivers, including an April 2027 IPF launch opportunity, an estimated $3.4B peak non-risk-adjusted Tyvaso opportunity in PAH and PH-ILD combined in 2030E, and a broader portfolio with Remodulin, Orenitram, Adcirca, and Unituxin.

United Therapeutics is exposed to concentrated reliance on the Tyvaso franchise, with Tyvaso DPI driving maximum revenue while Remodulin and Orenitram face competitive pressure from novel mechanisms, generic entrants, and Liquidia’s Yutrepia taking more PAH share than expected. Its growth case also depends on portfolio expansion that may not arrive on schedule, including slower-than-expected uptake in IPF/PPF, possible delay of TreSMI beyond FY27, and regulatory or prescribing setbacks for ralinepag across future indications. Fundamentally, the company also faces standard biotech risks plus considerable near-term legal risk that could threaten exclusivity of its primary source of top-line growth, while United States revenue concentration heightens the impact of any commercialization missteps.